Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02572986
Other study ID # DRL-USG02-P/2015
Secondary ID
Status Completed
Phase Phase 3
First received October 8, 2015
Last updated October 13, 2016
Start date September 2015
Est. completion date August 2016

Study information

Verified date October 2015
Source Dr. Reddy's Laboratories Limited
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Scabies is an infestation of the skin by the human itch mite (Sarcoptes scabiei). Diagnosis of scabies is made based on clinical symptoms, such as nocturnal itching, and appearance and distribution of the rash. Definitive diagnosis includes the microscopic identification of the mite, mite eggs, or mite fecal matter in the skin. Topical permethrin is considered the drug of choice for the treatment of scabies. It is a synthetic pyrethroid that is safe for use in adults and children 2 months and older.

This study will evaluate the therapeutic equivalence of a generic permethrin cream 5% to Elimite® in the Treatment of Scabies.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date August 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 2 Years and older
Eligibility Inclusion Criteria:

1. Signed Informed Consent that meets all criteria of current FDA regulations.

2. Male or non-pregnant, non-lactating female at least 2 years of age or older.

3. Diagnosis of active scabies by presence of a burrow and/or typical scabietic lesions at the classic sites of infestation.

4. Parasitological confirmation of clinical diagnosis with demonstration under light microscope of mites and/or their products (larvae, eggs or fecal material).

5. Symptom score of 2 or 3 on a 4-point rating scale of 0-3 for nocturnal itching.

6. Women must be either 1 year post-menopausal (no menstrual periods for at least 12 months), surgically sterile, or if they are of child-bearing potential, they must:

- Have been using systemic birth control, intrauterine device, or used barrier methods such as diaphragm plus spermicide or condom plus spermicide consistently, at least 14 days before study cream administration.

- Had a normal menstrual cycle for the month before start of treatment.

- Have a negative urine pregnancy test result upon entry into the study.

- Agree to use a medically accepted form of birth control (oral, implant, injectable or transdermal contraceptives, intrauterine device, condom plus spermicide, diaphragm plus spermicide) or practice abstinence throughout the study period.

7. Free from any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of adverse events.

8. Ability to apply study product to self or to other person if a child. If patient is a child, then parent/guardian will apply study product to him/her.

Exclusion Criteria:

1. Known hypersensitivity to permethrin cream or any of its components, ragweed or chrysanthemums, synthetic pyrethroids or pyrethrin.

2. Use of any systemic or topical acaricide 1 month before enrollment.

3. Patients with crusted/Norwegian scabies.

4. Patients with an underlying immunodeficient state (including prolonged treatment with corticosteroids), immunosuppressive disorders requiring therapy, severe systemic disease and history of HIV infection.

5. Any condition, medical, psychological, or social, that, in the Investigator's opinion, would interfere with participation in the study.

6. Women who are pregnant, planning pregnancy or lactating.

7. Family members of employees of the clinic or Investigator.

8. Patients who, in the opinion of the Investigator, would be non-compliant with the requirements of the study protocol.

9. Patients whose close personal contacts will not or are not willing to comply with standard of care for Scabies management.

10. Patients less than 2 years of age.

11. Patients or guardians of patients, who are unable or unwilling to give informed consent or assent respectively.

12. Receipt of any drug as part of a research study within 30 days before screening.

13. History of seizures.

14. Severe cutaneous bacterial or fungal infections requiring therapy (including systemic and topical antibiotics) or coexisting dermatological disorder that could interfere with the diagnosis and subsequent monitoring of scabies.

15. Treatment with systemic or topical corticosteroids less than 2 weeks and less than 1 week from enrollment, respectively.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Permethrin


Locations

Country Name City State
El Salvador Clinica Dermatologica San Salvador
El Salvador Clinica Dermatologica y Cirugia de Piel Santa Tecla, La Libertad
Panama Clinica Dermatologica Dra. Yariela Grajales Ciudad de Panama PanamaCity
United States Sun Rise Clinical Research, Inc Bell Gardens California
United States Derm Dx Center for Dermatology Hazleton Pennsylvania
United States Solutions Through Advanced Research Jacksonville Florida
United States L & C Professional Medical Research Institute Miami Florida
United States San Marcus Research Clinic, Incorporation Miami Florida
United States Vista Health Research, LLC Miami Florida
United States Havana Research Institute Pasadena California
United States Omni Dermatology Phoenix Arizona
United States Zain Research, LLC Richland Washington
United States Sun Research Institute San Antonio Texas

Sponsors (2)

Lead Sponsor Collaborator
Dr. Reddy's Laboratories Limited Novum Pharmaceutical Research Services

Countries where clinical trial is conducted

United States,  El Salvador,  Panama, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events assessment Day 28 Yes
Primary Proportion of patients with therapeutic cure (parasitological cure plus clinical cure) of scabies Day 28 No
Secondary The proportion of patients with no itch persistence Day 28 No
See also
  Status Clinical Trial Phase
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT05025696 - Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies N/A
Completed NCT04205669 - Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon Phase 4
Completed NCT02254564 - PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
Not yet recruiting NCT06404333 - Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15) Phase 2
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT05875441 - Efficacy and Safety Study of Moxidectin in Adults With Scabies Phase 2
Completed NCT02978508 - Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies. Phase 3
Recruiting NCT04332068 - Ivermectin Safety in Small Children Phase 2
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Not yet recruiting NCT06380452 - Therapy for Scabies With Two Differently Concentrated Permethrin Creams Phase 3
Completed NCT00604084 - Veron Scabies Education and Eradication Program N/A
Completed NCT02485717 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Completed NCT02485704 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Recruiting NCT05310734 - PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies Phase 4
Recruiting NCT04931680 - Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
Completed NCT06396507 - Sulfur vs. Different Regimes of Permethrin for Scabies Phase 3
Completed NCT05862701 - Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies Phase 1
Not yet recruiting NCT05500326 - Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) Phase 2
Recruiting NCT04814511 - Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin) Phase 3